價格 | ¥553 | ¥793 | ¥1230 |
包裝 | 1mg | 2mg | 5mg |
最小起訂量 | 1mg |
發(fā)貨地 | 上海 |
更新日期 | 2024-09-29 |
中文名稱:佐他莫司 | 英文名稱:Zotarolimus |
CAS:221877-54-9 | 品牌: TargetMol |
產(chǎn)地: 美國 | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
純度規(guī)格: ≥98% | 產(chǎn)品類別: 抑制劑 |
貨號: T6033 |
名稱 | Zotarolimus |
描述 | Zotarolimus (ABT-578), an analogue of rapamycin, inhibits FKBP-12 (IC50= 2.8 nM). |
細胞實驗 | Cell proliferation is assayed by measuring tritiated thymidine incorporation in vitro. Human coronary artery cells (hCa) are seeded into tissue culture flasks for expansion and applied to 96-well plates at desired density in complete media (5000 hCaSMC; 10 000 hCaEC). After 2 days, complete media is replaced with incomplete media to synchronize cells and induce G0 state. Two days later, incomplete media are removed and replaced with complete media (serum/growth factors) to induce G0 to G1 transition. Complete media also contain drug at desired concentrations to determine its effects on cell proliferation. On day 7, 3H-thymidine is added to cells to monitor DNA synthesis, and cells are harvested after overnight incorporation of radioactivity. After an incubation period of 72 h, 25 μL (1 μCi/well) of 3H-thymidine are added to each well. The cells are incubated at 37°C for 16-18 h to allow for incorporation of 3H-thymidine into newly synthesized DNA and the cells harvested onto 96-well plates containing bonded glass fibre filters . The filter plates are air-dried overnight, MicroScint-20 (25 μL) added to each filter well and counted. Drug activity is determined by the inhibition of 3H-thymidine incorporation into newly synthesized DNA relative to cells grown in complete media. (Only for Reference) |
激酶實驗 | zotarolimus (10 pM-1 μM) in buffer A (2% BSA and 0.2% Tween-20 in D-PBS) is used in the assay of Binding Affinity to FKBP12. |
動物實驗 | Male Sprague-Dawley rats was administrate by intravenous or oral Zotarolimus(2.5 mg/kg)dissolved inethanol: propylene glycol: cremophor EL: D5W vehicle (20: 30: 2: 48, by volume). |
體外活性 | 在平滑肌細胞(IC50=2.9 nM)和內(nèi)皮細胞(IC50=2.6 nM)中,Zotarolimus有效抑制細胞增殖。 |
體內(nèi)活性 | Zotarolimus 強效抑制劑,對輔助性遲發(fā)型超敏反應(DTH)(ED50=1.72 mg/kg/day)、實驗性自身免疫性腦炎(EAE)(ED50=1.17 mg/kg/day)、以及心臟移植排斥反應(ED50=3.71 mg/kg/day)表現(xiàn)出顯著的抑制作用。 |
存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | Ethanol : 93 mg/mL (96.3 mM) DMSO : 93 mg/mL (96.3 mM) H2O : < 1 mg/mL (insoluble or slightly soluble) |
關鍵字 | coronary | ABT 578 | drug-eluting | inhibit | artery | disease | restenosis | Rapamycin | Zotarolimus | ABT578 | immunosuppressant | A-179578 | stents | A179578 | Inhibitor |
相關產(chǎn)品 | Rapamycin | L-Leucine | Sapanisertib |
相關庫 | 經(jīng)典已知活性庫 | 已知活性化合物庫 | 激酶抑制劑庫 | 抗衰老化合物庫 | 藥物功能重定位化合物庫 | 抗癌臨床化合物庫 | 抗癌藥物庫 |
成立日期 | 2013-04-18 (12年) | 注冊資本 | 566.265100萬人民幣 |
員工人數(shù) | 100-500人 | 年營業(yè)額 | ¥ 1億以上 |
主營行業(yè) | 天然產(chǎn)物,生化試劑,分子生物學,分子砌塊,生物技術服務 | 經(jīng)營模式 | 貿(mào)易,工廠,試劑,定制,服務 |
產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
---|---|---|---|---|
¥16000 |
VIP9年
|
湖北威德利化學試劑有限公司
|
2024-11-08 | |
詢價 |
VIP6年
|
成都彼樣生物科技有限公司
|
2024-11-07 | |
詢價 |
VIP5年
|
眾鑫辰實(武漢)科技有限公司
|
2024-11-07 | |
詢價 |
南京百鑫德諾生物科技有限公司
|
2024-09-26 | ||
¥308.90 |
VIP1年
|
上海阿拉丁生化科技股份有限公司
|
2024-08-16 |